Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 240
Views pdf: 122
DOI: https://doi.org/10.51298/vmj.v530i1B.6754
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. N., Đặng, T. T. H., Nguyễn, V. L., Hoàng, P. Q. T., & Nguyễn, T. P. T. (2023). GENERAL CHARACTERISTICS AND RESPONSE OF PATIENTS WITH RECURENT METASTATIC RIGHT COLON CANCER TREATED WITH BEVACIZUMAB – FOLFIRI AT 108 MILITARY CENTRAL HOSPITAL. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6754

GENERAL CHARACTERISTICS AND RESPONSE OF PATIENTS WITH RECURENT METASTATIC RIGHT COLON CANCER TREATED WITH BEVACIZUMAB – FOLFIRI AT 108 MILITARY CENTRAL HOSPITAL

Thanh Ngọc Nguyễn1,, Thị Thu Hiền Đặng1, Việt Long Nguyễn1, Phan Quỳnh Trang Hoàng1, Thị Phương Thảo Nguyễn1
1 108 Military Central Hospital

Main Article Content

Abstract

Objectives: To assess some general characteristics, tumor response, and association between response to some factors in patients with recurent metastatic right colon cancer treated with Bevacizumab-FOLFIRI. Subjects and methods: A retrospective and prospective study was done on 35 patients with recurrent metastatic right colon cancer, who were received Bevacizumab - FOLFIRI treatment at 108 Military Central Hospital from January 2021 to May 2023. Result: the complete response rate was 14.3%, the overall response rate was 31.4%; histopathology, number of metastatic organs, CEA concentration before and after treatment are some factors that affect response rate. Conclusion: Bevacizumab-FOLFIRI regimen is an effective option in patients with recurrent metastatic right colon cancer.

Article Details

Keywords

metastatic colon cancer, Bevacizumab, FOLFIRI.

References

1. Hyuna Sung et al (2021). Global Cancer Statistics 2020: GLOBOCAN Estimate of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries. CA Cancer J Clin 2021; 71(3):209-249.
2. Cervantes A. et al (2022). Metastatic Colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34(1): 10-32.
3. Nguyễn Quang Thái (2007), Nghiên cứu giá trị một số phương pháp chẩn đoán và kết quả sống 5 năm sau điều trị phẫu thuật ung thư đại tràng, Luận án tiến sỹ y học, Học viện quân y.
4. Herbert Hurwitz et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23): 2335-2342.
5. Sobrero A., Ackland S., Clarke S. và cộng sự. (2009). Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology, 77(2), 113–119.
6. Nguyễn Thị Sang và CS (2019). Đánh giá đáp ứng của Bevacizumab kết hợp XELOX trên bệnh nhân ung thư đại trực tràng giai đoạn muộn, Tạp chí Ung thư học Việt Nam, 1, 344-347.
7. Sasaki S1, Ishimaru M, Suzuki H, Ogawa M, Sato Y. Significance of CEA to predict the effect of chemotherapy with bevacizumab, Gan To Kagaku Ryoho 2010 Mar, 37(3), 463-7.